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SUMMARY: Isolation and determination of the nucleotide sequence of hemagglutinin (HA) of the
pandemic (H1N1) 2009 influenza viruses found in Nagasaki, Japan, were conducted. The alignment
results of the predicted HA amino acid sequences of these strains compared to the known global isolates
revealed 5 specific amino acid differences located within the antigenic sites. The phylogenetic analyses
revealed that the majority of the Nagasaki isolates could be classified into 6 phylogenetic clusters.
Almost all isolates collected in the early season were classified into cluster I, which apparently originated
from A/Nagasaki/HA-6/2009 isolated from a patient who returned from the Philippines. This cluster
ceased to spread after November 2009. Between the end of August 2009 and January 2010, 5 new
phylogenetic clusters (II–VI) emerged with viruses from different origins, and cluster III continuously
advanced until March 2010. These results suggest that the onset of the influenza epidemic in Nagasaki
originated from patient(s) who returned from the Philippines, and subsequently, various imported
strains from different origins sustained the virus spread. Among the Nagasaki isolates,
A/Nagasaki/HA-58/2009 having an H275Y mutation in the neuraminidase gene, which confers
resistance to oseltamivir, was isolated. This is the first report in which an oseltamivir-resistant pandemic
H275Y mutant was identified in Nagasaki Prefecture.
INTRODUCTION
The pandemic (H1N1) 2009 influenza viruses were
first identified in Mexico and the United States in mid-
April 2009. The virus quickly spread throughout the hu-
man population, and the number of patients increased
to hundreds of thousands, and hundreds of deaths had
been reported by May 5, 2009 (1). Consequently, the
World Health Organization (WHO) raised the influenza
pandemic alert level to phase 6 on June 11, 2009. In
Japan, the Ministry of Health, Labour and Welfare en-
forced a quarantine strategy on April 28, 2009 for
patients with pandemic (H1N1) 2009 influenza (2). In
Japan, the first patients with pandemic influenza were
identified at the Narita airport among travelers who
returned from Canada on May 9, 2009, and many more
pandemic influenza patients were subsequently identi-
fied (3). In Nagasaki, the Nagasaki Prefectural Govern-
ment quarantined patients who visited the hospital with
symptoms suspicious for influenza starting on May 18,
2009. The first case of pandemic influenza in Nagasaki
was identified among travelers who returned from for-
eign countries on June 16, 2009. However, the spread of
the pandemic (H1N1) 2009 influenza viruses in
Nagasaki was not detected until July 20, 2009. This im-
plies that the initial quarantine was effective for
preventing the spread of the virus. However, on July 20,
2009, the spread of the pandemic (H1N1) 2009 influenza
viruses began among the younger individuals who at-
tended the summer festival held in Nagasaki, which was
attended by approximately 2,000 people.
The influenza A virus surface glycoprotein hemag-
glutinin (HA), which plays a major role in viral attach-
ment and evasion from neutralizing antibody responses,
is under selective pressure to mutate to escape from the
host immune system. The HA protein consists of 2
domains: the globular head (composed of most of the
antigenic HA1 polypeptide of HA) and the long fibrous
stem (comprised mostly of the HA2 polypeptide) (4,5).
The HA1 domain of the influenza HA protein is the
most rapidly evolving region of these viruses. The HA1
domain in H1-subtype strains has 4 additional antigenic
sites, including Sa, Sb, Ca, and Cb, that are determined
on the basis of the assessment of antigenic variations of
virus mutants (4–6). Point mutations in this domain
may induce antigenic changes (7,8), known as antigenic
drift. Because of the high morbidity and mortality due
to influenza epidemics, monitoring of the accumulated
antigenic variations in circulating influenza viruses is
important for predicting epidemics, severity, and for the
design of future vaccines.
The other influenza A virus surface glycoprotein,
neuraminidase (NA) (9), which is composed of a
tetramer comprising a bulky head attached to a stalk,
plays a major role in allowing the release of progeny
viruses from an infected cell's surface by digestion of
the terminal sialic acids from glycoconjugates on both
cell receptors and the viral HA proteins. Thus far, sever-
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al NA inhibitors, including zanamivir and oseltamivir,
which bind to the active site of NA, have been produced
and used for the treatment of influenza-infected
patients (10). However, oseltamivir-resistant influenza
virus mutants have been identified in A-type as well as
B-type viruses isolated from patients (11–13). Among
these viruses, mutants of NA possessing H275Y (substi-
tution of histidine by tyrosine at residue 275 in the NA
protein) were identified, which showed high tolerance to
oseltamivir (12,13). The spread of oseltamivir-resistant
seasonal H1N1 influenza viruses was very rapid, result-
ing in oseltamivir resistance in more than 90z of the
seasonal H1N1 influenza viruses isolated during the
2008/2009 season (14).
In Japan, seasonal H1N1 influenza viruses carrying
the above-mentioned mutation were identified among
2.6z of the isolated influenza viruses during the
2007/2008 season; however, more than 99z of the
viruses identified during the 2008/2009 season were
oseltamivir resistant (14). During the pandemic (H1N1)
2009, oseltamivir-resistant pandemic strains were also
rarely identified in some foreign countries and in Japan
(15). It can be easily speculated that the oseltamivir-
resistant pandemic (H1N1) 2009 influenza viruses may
spread rapidly at any time. Therefore, monitoring the
possible emergence of oseltamivir-resistant viruses is im-
portant.
To characterize the properties of the pandemic in-
fluenza viruses in Nagasaki, we analyzed the HA se-
quences of Nagasaki isolates. Furthermore, we aimed to
determine how the pandemic influenza viruses spread in
Nagasaki. This analysis can provide a good simulation
for estimating the spread of newly emerging pandemic
influenza viruses in a region far from the pandemic ori-
gin. In the present study, we conducted sequencing and
phylogenetic analyses of the HA genes of the pandemic
(H1N1) 2009 influenza viruses isolated from patients in
Nagasaki (collected from July 2009 to March 2010). We
also analyzed partial nucleotide NA sequences, includ-
ing the H275Y coding region, to identify oseltamivir-
resistant mutants. Our data clearly show that the initial
quarantine strategy was effective but insufficient to
completely prevent the spread of the pandemic (H1N1)
2009 influenza viruses in Nagasaki. Moreover, only one
oseltamivir-resistant H275Y mutant was identified dur-
ing the pandemic season in Nagasaki, and no additional
spreading of the virus occurred during the time of our
analysis.
MATERIALS AND METHODS
Clinical samples and virus isolation: Nasopharyngeal
or throat swab specimens from influenza patients were
collected between July 2009 and March 2010 at the
Nagasaki Municipal Public Health and Environment
Laboratory. The patients were confirmed to be infected
with the pandemic (H1N1) 2009 influenza virus by im-
munochromatography and polymerase chain reaction
(PCR) (Table 1). The total number of specimens ob-
tained was 94, and of these, 88 were confirmed to be
positive for the pandemic (H1N1) 2009 influenza virus.
Isolation of the virus was achieved from 75 positive
specimens. The details of these 75 patients are summa-
rized in Table 1. The age of the patients ranged from 0
to 63 years. Of these patients, 36 were men and 39 were
women. In patient HA-58, aggravated symptoms
despite treatment with oseltamivir were recorded.
Patients who had symptoms after participating in the
summer festival held in Nagasaki on July 20, 2009, are
indicated by boxes in Table 1.
Specimens were filtered, and the resulting samples
were inoculated onto Madin-Darby Canine Kidney
(MDCK) cells with trypsin. Upon observation for char-
acteristic cytopathic effects in MDCK cells, the virus-
containing supernatants were collected. The virus isola-
tion rates in the early (collected between July and Au-
gust, isolates stored at 49C) and late (collected between
January and March, isolates stored at －809C) pandem-
ic seasons were high (85.3 and 87.1z, respectively),
whereas the rate in the mid-pandemic season (collected
between September and December, isolates stored at
49C) was slightly lower (58.8z) (data not shown). The
isolated viruses were named on the basis of their collec-
tion numbers as summarized in Table 1.
Genomic sequence analysis: Viral RNAs were extract-
ed from the culture supernatants or swabs using a
QIAamp Viral RNA Mini Kit (Qiagen, Valencia, Calif.,
USA). The resulting RNA was subjected to cDNA syn-
thesis using HA primer 1 (5?-TATTCGTCTCAGGGA
GCAAAAGCAGGDKB-3?) and M-MLV Reverse
Transcriptase (Invitrogen, Carlsbad, Calif., USA). Sub-
sequently, the resulting cDNA was used for PCR, which
was performed in a buffer containing the respective
primer sets with Pfu DNA polymerase (Bioacademia,
Osaka, Japan) to amplify the HA genes. Two primer
sets for the 5?-terminal one-third of HA (HA primer 1
and HA primer 2, 5?-CAGCACTAGTAGATGGATG
G-3?) and for the 3?-terminal two-thirds of HA (HA
primer 3, 5?-ACCCAAAGCTCAGCAAATCC-3?, and
HA primer 4, 5?-ATATCGTCTCGTATTAGTAGAA
ACAAGGKKSTT-3?) were used. Amplicons of 515 bp
and 1,199 bp, respectively, were amplified. For the am-
plification of partial NA genes, including a region corre-
sponding to the H275Y mutation, PCR was performed
using cDNA obtained as described above and a primer
set for NA (NA primer 1, 5?-ATCGAACCCTAAT
GAGC-3? and NA primer 2, 5?-TGCATATGTAT
CCTATCTG-3?), resulting in a 492-bp amplicon. Direct
sequencing of these amplicons was performed using an
Applied Bio 3100-Avant Genetic Analyzer (Applied
Biosystems, Foster City, Calif., USA).
Phylogenetic tree analysis: We analyzed the phyloge-
netic relationship of the nucleotide sequences of HA
(complete open reading frame) of 75 viruses collected in
Nagasaki and compared it with those from global iso-
lates collected between July 2009 and March 2010 by ap-
plying the maximum-likelihood method using the
phyML software program (16,17). The model, branch
support, tree searching operations, and starting tree
parameters for the phyML software program were set to
GTR, bootstrap with 1,000 replicates, NNI, and BioNJ,
respectively. Bootstrap values that had a probability
value higher than 50z were added in the tree. The HA
sequence data from 107 global isolates of the pandemic
(H1N1) 2009 influenza viruses collected between July 1,
2009 and March 31, 2010 were obtained from the In-
fluenza Virus Resource Database (NCBI) on May 3,
2010. The genetic divergence in the viruses was very
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Table 1. Data of the specimens from influenza patients in Nagasaki City
Specimen (strain) Date ofcollection Age Sex Description
Accession no. of
HA sequences
A/Nagasaki/HA-4/2009 5/7/2009 29 male Travel to Indonesia AB530161
A/Nagasaki/HA-6/2009 13/7/2009 55 male Travel to Philippines AB530249
A/Nagasaki/HA-9/2009 23/7/2009 27 male Travel to Philippines AB530461
A/Nagasaki/HA-10/2009 23/7/2009 23 male Participated in Summer festival AB530462
A/Nagasaki/HA-11/2009 23/7/2009 59 female — AB530463
A/Nagasaki/HA-12/2009 24/7/2009 21 female Participated in Summer festival AB530464
A/Nagasaki/HA-13/2009 24/7/2009 22 female Participated in Summer festival AB530465
A/Nagasaki/HA-14/2009 24/7/2009 29 male Participated in Summer festival AB530466
A/Nagasaki/HA-15/2009 24/7/2009 17 female Participated in Summer festival AB530467
A/Nagasaki/HA-16/2009 25/7/2009 23 female — AB530468
A/Nagasaki/HA-17/2009 27/7/2009 17 female — AB530469
A/Nagasaki/HA-18/2009 27/7/2009 18 female — AB530470
A/Nagasaki/HA-22/2009 29/7/2009 23 male — AB530471
A/Nagasaki/HA-24/2009 29/7/2009 22 male — AB535738
A/Nagasaki/HA-25/2009 30/7/2009 7 male — AB530472
A/Nagasaki/HA-26/2009 30/7/2009 9 female — AB530473
A/Nagasaki/HA-27/2009 30/7/2009 18 female — AB530474
A/Nagasaki/HA-28/2009 30/7/2009 6 male — AB530475
A/Nagasaki/HA-29/2009 30/7/2009 17 male — AB530476
A/Nagasaki/HA-30/2009 30/7/2009 22 female — AB535739
A/Nagasaki/HA-31/2009 3/8/2009 15 female — AB530477
A/Nagasaki/HA-32/2009 3/8/2009 17 male — AB530478
A/Nagasaki/HA-33/2009 3/8/2009 8 male — AB530479
A/Nagasaki/HA-34/2009 3/8/2009 3 male — AB530480
A/Nagasaki/HA-35/2009 3/8/2009 10 female — AB530481
A/Nagasaki/HA-36/2009 5/8/2009 12 female — AB530482
A/Nagasaki/HA-37/2009 5/8/2009 15 female — AB535740
A/Nagasaki/HA-38/2009 10/8/2009 5 male — AB530483
A/Nagasaki/HA-39/2009 10/8/2009 63 female — AB530484
A/Nagasaki/HA-40/2009 17/8/2009 6 male — AB530485
A/Nagasaki/HA-41/2009 17/8/2009 5 male — AB530486
A/Nagasaki/HA-42/2009 20/8/2009 34 female — AB530487
A/Nagasaki/HA-44/2009 20/8/2009 6 male — AB530488
A/Nagasaki/HA-46/2009 31/8/2009 13 male — AB540654
A/Nagasaki/HA-48/2009 10/9/2009 1 female — AB535742
A/Nagasaki/HA-49/2009 14/9/2009 3 male — AB539047
A/Nagasaki/HA-50/2009 6/10/2009 12 male — AB535743
A/Nagasaki/HA-52/2009 9/10/2009 6 female — AB535744
A/Nagasaki/HA-53/2009 9/10/2009 10 male — AB535745
A/Nagasaki/HA-56/2009 22/10/2009 2 months female — AB539046
A/Nagasaki/HA-57/2009 26/10/2009 13 male — AB536768





A/Nagasaki/HA-59/2009 27/10/2009 2 months female — AB535746
A/Nagasaki/HA-60/2009 27/10/2009 8 female — AB535747
A/Nagasaki/HA-62/2009 29/10/2009 3 months female — AB536770
A/Nagasaki/HA-63/2009 29/10/2009 18 male — AB535748
A/Nagasaki/HA-64/2009 27/11/2009 9 female — AB558535
A/Nagasaki/HA-65/2009 3/12/2009 56 male — AB558536
A/Nagasaki/HA-10-1/2010 4/1/2010 9 male — AB551871
A/Nagasaki/HA-10-2/2010 4/1/2010 6 male — AB551872
A/Nagasaki/HA-10-3/2010 4/1/2010 9 male — AB551873
A/Nagasaki/HA-10-4/2010 4/1/2010 4 female — AB551874
A/Nagasaki/HA-10-5/2010 12/1/2010 13 female — AB551875
A/Nagasaki/HA-10-6/2010 12/1/2010 2 male — AB551876
A/Nagasaki/HA-10-7/2010 12/1/2010 21 female — AB551877
A/Nagasaki/HA-10-11/2010 12/1/2010 12 male — AB551880
A/Nagasaki/HA-10-9/2010 18/1/2010 0 female — AB551878
A/Nagasaki/HA-10-10/2010 18/1/2010 13 female — AB551879
A/Nagasaki/HA-10-12/2010 18/1/2010 2 months female — AB551881
A/Nagasaki/HA-10-13/2010 18/1/2010 9 female — AB551882
A/Nagasaki/HA-69/2010 20/1/2010 18 male — AB551883
A/Nagasaki/HA-10-14/2010 1/2/2010 11 male — AB558537
A/Nagasaki/HA-10-15/2010 1/2/2010 13 female — AB558538
A/Nagasaki/HA-10-17/2010 8/2/2010 4 female — AB558539
A/Nagasaki/HA-10-18/2010 15/2/2010 9 male — AB558540
A/Nagasaki/HA-10-19/2010 15/2/2010 6 male — AB558541
A/Nagasaki/HA-10-20/2010 15/2/2010 16 female — AB558542
A/Nagasaki/HA-10-21/2010 22/2/2010 6 female — AB558543
A/Nagasaki/HA-10-22/2010 1/3/2010 12 male — AB558544
A/Nagasaki/HA-10-24/2010 8/3/2010 6 female — AB558545
A/Nagasaki/HA-10-25/2010 8/3/2010 10 female — AB558546
A/Nagasaki/HA-10-26/2010 15/3/2010 4 male — AB558547
A/Nagasaki/HA-10-27/2010 15/3/2010 3 female — AB558548
A/Nagasaki/HA-10-28/2010 23/3/2010 13 female — AB558549
A/Nagasaki/HA-10-30/2010 29/3/2010 15 male — AB558550
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small, as illustrated by the fact that the bootstrap values
for the nodes were in general very low. This applied to
most of the phylogenetic analyses of these newly
emerged viruses. Hence, we could not use the bootstrap
values as references to designate the Nagasaki clusters.
Therefore, the designation of the Nagasaki clusters (I to
VI) was conducted by connecting the sub-clusters of
evolutionarily close Nagasaki isolates.
We also analyzed the phylogenetic relationship of the
nucleotide HA sequences of 14 Nagasaki isolates (classi-
fied as cluster I) by the above-mentioned maximum-
likelihood method and compared it with those of the
isolates A/Philippines/2001/2009, Mexican (7 strains),
and American (11 strains), which were isolated between
April and May 2009 (initially spreading viruses) ob-
tained from the Influenza Virus Resource Database on
May 3, 2010.
In vitro oseltamivir-resistance assay: To determine
the relative sensitivities of the viruses to oseltamivir in
liquid culture, MDCK cells seeded in 96-well plates were
challenged with approximately 100 of 50z tissue cul-
ture infective dose (TCID50) of each virus. Serial 3-fold
dilutions of oseltamivir were added to each well in
duplicate. The culture plates were incubated for 3 days
at 379C, and the growth of the virus was detected by
crystal violet staining and absorbance at a wavelength of
560 nm with an infinite M200 spectrometer (TECAN,
Kanagawa, Japan). The concentrations of oseltamivir
ranged from 0.2 mM to 1,000 mM.
Nucleotide sequence accession numbers: The nucleo-
tide sequences of HA determined in this study can be
found in the DDBJ, EMBL, and GenBank databases
under the indicated accession numbers summarized in
Table 1.
RESULTS
Sequence analysis and amino acid differences: The
nucleotide sequences of all HA genes of the viruses col-
lected from patients in Nagasaki revealed a sequence
identity that was higher than 99.5z compared to other
pandemic (H1N1) 2009 influenza viruses. These data in-
dicated that the isolated viruses were indeed pandemic
influenza viruses. The mean nucleotide divergences
(mean ± SE) within Nagasaki isolates and in compari-
son to the pandemic standard A/California/07/2009
strain were 0.00370 ± 0.00064 and 0.00518 ± 0.00137,
respectively. The divergences within each isolation
period (July to September, October to December, and
January to March) were 0.00136 ± 0.00040, 0.00386 ±
0.00083, and 0.00534 ± 0.00095, respectively (data not
shown). These results were analyzed using the maximum
composite likelihood method and the MEGA version
4.0 software package with 500 bootstrap replicates (18).
The predicted amino acid sequences of HA of the isolat-
ed viruses in Nagasaki did not contain a conserved argi-
nine or a stretch of basic amino acids in the cleavage
site, whereas a trypsin-like protease cleavage site, which
can be cleaved by proteases existing in the respiratory
tract (PSIQSR/GLF amino acid positions of 339 to
347), has been identified without any mutations (data
not shown). Furthermore, a single potential N-glycosy-
lation site (N104) in the globular head region of HA cor-
responding to one of the antigenic characteristics was
completely conserved among these strains, as reported
for the pandemic 1918 case, as well as in recent seasonal
human (H1N1) viruses. Other potential 4-5 N-glycosyla-
tion sites (N-Xaa-S/T, where Xaa is any amino acid ex-
cept P) that have been acquired in several recent
seasonal (H1N1) viruses (19) were not found in the pan-
demic (H1N1) 2009 influenza viruses (data not shown).
Amino acid alignment of the HA of Nagasaki isolates
against global isolates was performed, and the results
are summarized in Table 2. The amino acid differences
of the HA of Nagasaki isolates were I4K, D52G, K53N,
T106M, S138I, N146D, V149E, A156D, A203T,
D204G, A214T, T220S, D239E, A273T, N311D,
P314S, P321S, G360E, E391K, N461K, T491P, I527V,
and I564K. Among these amino acid differences, D52G,
T106M, D239E, P314S, and E391K were also observed
in several other foreign isolates (data not shown).
A156D, A203T, D204G, T220S, and D239E were locat-
ed within the antigenic HA1 sites (4–6). In the early pan-
demic season (July to August 2009), the amino acid
differences S138I, T220S, and P321S were mainly ob-
served, and S138I and P321S continued to be observed
until October 2009.
Several other amino acid differences (D239E, P314S,
and I527V) began to be observed from the end of
August. The amino acid differences I4K and A214T be-
gan to be observed from the beginning and the end of
October 2009, respectively. Amino acid differences in
the antigenic sites (4–6) of Ca2 (A156D in A/Nagasaki/
HA-10-4, 5, and 10/2010) and of Sb (A203T in A/
Nagasaki/HA-10-13/2010 and D204G in A/Nagasaki/
HA-10-5, 6, and 9/2010) were frequently observed in
strains collected between January 4 and 18, 2010. From
mid-January until the end of February 2010, other ami-
no acid differences (D52G, N146D, V149E, A203T,
N311D, E391K, T491P, and I564K) were primarily ob-
served. The variation rate tended to change at an ap-
proximately 2-month interval. These strains likely origi-
nated outside of Nagasaki.
The analyses of partial NA sequences revealed that an
amino acid substitution, H275Y, which is known to
confer resistance to oseltamivir, was found in strain
A/Nagasaki/HA-58/2009 (Table 1). This strain was the
only one that had the mutation among 75 Nagasaki iso-
lates.
Phylogenetic tree analysis: Analysis of the phyloge-
netic relationship was based on nucleotide sequences of
HA of the isolated viruses and carried out by the max-
imum-likelihood method against sequences from global
isolates. Almost all viruses isolated in Nagasaki City
could be classified into 6 clusters (I–VI) (Fig. 1). Two
strains, A/Nagasaki/HA-4/2009 and A/Nagasaki/HA-
9/2009, isolated from patients who returned from
abroad, appeared at different positions compared with
other Nagasaki isolates. These patients had apparently
been infected in foreign countries. Almost all Nagasaki
isolates collected during the earlier season (July to
October 2009) were classified into cluster I, which
evolutionarily originated from A/Nagasaki/HA-6/
2009, which was isolated from a patient who returned
from the Philippines. The spread of this cluster started
after July 20, 2009, and advanced until the end of
October of 2009. Sixteen strains in cluster I (A/
Nagasaki/HA-11, 13, 24, 27, 30–40, and 42/2009) had
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Table 2. The amino acid sequence of HA in the Nagasaki isolates
Strain name Date of
collection
Amino acid diffrences in Nagasaki isolates1)
4 52 53 106 138 146 149 156 (a) 203 (b) 204 (b) 214 220 (c) 239 (a) 273 311 314 321 360 391 461 491 527 564
A/New York/3191/2009
(control) 25/4/2009 I D K T S N V A A D A T D A N P P G E N T I I
A/Nagasaki/HA-4/2009 5/7/2009 — — — — — — — — — — — — — — — — — — — — — — —
A/Nagasaki/HA-6/2009 13/7/2009 — — — — — — — — — — — S — — — — — — — — — — —
A/Nagasaki/HA-9/2009 23/7/2009 — — — — — — — — — — — — — — — — — — — — — — —
A/Nagasaki/HA-10/2009 23/7/2009 — — N — — — — — — — — — — — — — S — — — — — K
A/Nagasaki/HA-11/2009 23/7/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-12/2009 24/7/2009 — — — — I — — — — — — S — — — — S — — — — — —
A/Nagasaki/HA-13/2009 24/7/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-14/2009 24/7/2009 — — — — I — — — — — — S — — — — S — — — — — K
A/Nagasaki/HA-15/2009 24/7/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-16/2009 25/7/2009 — — — — I — — — — — — S — — — — S — — — — — —
A/Nagasaki/HA-17/2009 27/7/2009 — — N — — — — — — — — S — — — — S — — — — — —
A/Nagasaki/HA-18/2009 27/7/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-22/2009 29/7/2009 — — — — I — — — — — — S — — — — S — — — — — —
A/Nagasaki/HA-24/2009 29/7/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-25/2009 30/7/2009 — — — — — — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-26/2009 30/7/2009 — — — — I — — — — — — — — — — — — — — — — — —
A/Nagasaki/HA-27/2009 30/7/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-28/2009 30/7/2009 — — — — I — — — — — — S — — — — S — — — — — —
A/Nagasaki/HA-29/2009 30/7/2009 — — — — I — — — — — — S — — — — — — — — — — —
A/Nagasaki/HA-30/2009 30/7/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-31/2009 3/8/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-32/2009 3/8/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-33/2009 3/8/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-34/2009 3/8/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-35/2009 3/8/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-36/2009 5/8/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-37/2009 5/8/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-38/2009 10/8/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-39/2009 10/8/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-40/2009 17/8/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-41/2009 17/8/2009 — — — — I — — — — — — — — — — — S — — — — V —
A/Nagasaki/HA-42/2009 20/8/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-44/2009 20/8/2009 — — — — — — — — — — — — E — — S — — — K — — —
A/Nagasaki/HA-46/2009 31/8/2009 — — N — — — — — — — — — — — — — — — — — — — —
A/Nagasaki/HA-48/2009 10/9/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-49/2009 14/9/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-50/2009 6/10/2009 — — — — — — — — — — — — — — — — — — — — — — —
A/Nagasaki/HA-52/2009 9/10/2009 — — — — — — — — — — — — E — — S — — — — — V —
A/Nagasaki/HA-53/2009 9/10/2009 K — — — — — — — — — — — — — — S — — — — — V —
A/Nagasaki/HA-56/2009 22/10/2009 — — — — — — — — — — T — — — — — — — — — — — —
A/Nagasaki/HA-57/2009 26/10/2009 — — — — — — — — — — T — — — — — — — — — — — —
A/Nagasaki/HA-58/2009 27/10/2009 — — — — I — — — — — — — — — — — S — — — — — —
A/Nagasaki/HA-59/2009 27/10/2009 — — — — — — — — — — T S — — — — — — — — — — —
A/Nagasaki/HA-60/2009 27/10/2009 — — — — I — — — — — — S — — — — S — — — — — —
A/Nagasaki/HA-62/2009 29/10/2009 — — — M — — — — — — — — — — — — — — — — — — —
A/Nagasaki/HA-63/2009 29/10/2009 — — — — — — — — — — T S — — — — — — — — — — —
A/Nagasaki/HA-64/2009 27/11/2009 — — — — — — — — — — T — — — — — — — — — — — —
A/Nagasaki/HA-65/2009 3/12/2009 — — — — — — — — — — — — — — — — — — — — — — —
A/Nagasaki/HA-10-1/2010 4/1/2010 — — — — — — — — — — — — — — — — — — — — — — —
A/Nagasaki/HA-10-2/2010 4/1/2010 — — — — — — — — — — — — — — — — — — — — — — —
A/Nagasaki/HA-10-3/2010 4/1/2010 — — — — — — — — — — — — — — — — — — — — — — —
A/Nagasaki/HA-10-4/2010 4/1/2010 — — — — — — — D — — — — — — — — S E — — — — —
A/Nagasaki/HA-10-5/2010 12/1/2010 — — — — — — — D — G — — — — — — S — — — — — —
A/Nagasaki/HA-10-6/2010 12/1/2010 — — — — — — — — — G — S — — — — — — — — — — K
A/Nagasaki/HA-10-7/2010 12/1/2010 — — — — — — E — — — — — — — — — — — K — — — —
A/Nagasaki/HA-10-11/2010 12/1/2010 — — — — — — — — — — T — — — — — — — — — — — —
A/Nagasaki/HA-10-9/2010 18/1/2010 — — — — — — — — — G T — — — — — — — — — — — —
A/Nagasaki/HA-10-10/2010 18/1/2010 — — — — — — — D — — — — — — — — S — — — — — —
A/Nagasaki/HA-10-12/2010 18/1/2010 — — — — — — — — — — — — — — — — — — — — P — —
A/Nagasaki/HA-10-13/2010 18/1/2010 — — — — — — — — T — — — — — — — — — K — — — —
A/Nagasaki/HA-69/2010 20/1/2010 — — — — — — — — — — — — — — D — — — — — — — —
A/Nagasaki/HA-10-14/2010 1/2/2010 — — — — — — — — — — T — — — — — — — — — — — —
A/Nagasaki/HA-10-15/2010 1/2/2010 — — — — — — E — — — — — — — — — — — K — — — —
A/Nagasaki/HA-10-17/2010 8/2/2010 — — — — — — E — — — — — — — — — — — K — — — K
A/Nagasaki/HA-10-18/2010 15/2/2010 — — — — — — — — — — — — — — — — — — K — — — —
A/Nagasaki/HA-10-19/2010 15/2/2010 — — — — — — — — — — — — — — — — — — — — — — —
A/Nagasaki/HA-10-20/2010 15/2/2010 — G — — — D — — — — — — — — — — — — — — — — —
A/Nagasaki/HA-10-21/2010 22/2/2010 — — — — — — — — — — — — — — — — — — K — — — —
A/Nagasaki/HA-10-22/2010 1/3/2010 — — — — — — — — — — — — — — — — — — — — — — —
A/Nagasaki/HA-10-24/2010 8/3/2010 — — — — — — — — — — — — — T — — — — — — — — K
A/Nagasaki/HA-10-25/2010 8/3/2010 — — — — — — — — — — — — — — — — — — K — — — K
A/Nagasaki/HA-10-26/2010 15/3/2010 — — — — — — — — — — — — — T — — — — — — — — K
A/Nagasaki/HA-10-27/2010 15/3/2010 — — — — — — — — — — — — — — — — — — — — — — K
A/Nagasaki/HA-10-28/2010 23/3/2010 — — — — — — — — — — — — — T — — — — — — — — —
A/Nagasaki/HA-10-30/2010 29/3/2010 — — — — — — — — — — — — — — — — — — — — — — K
1): Amino acid residues located in the Ca2, Sb, and Ca1 regions are indicated as (a), (b), and (c), respectively.
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Fig. 1. Phylogenetic tree of the HA genes of the pandemic (H1N1) 2009 influenza viruses isolated in Nagasaki,
Japan, between July 2009 and March 2010, determined by the maximum-likelihood method. Phylogenetic
relationship of the HA sequences of Nagasaki isolates against those from global isolates collected between July
2009 and March 2010 was analyzed. Nagasaki clusters (I to VI) were indicated by ellipses and were highlighted.
The amino acid mutations within antigenic sites of the Nagasaki isolates were plotted in the tree. The bar indicates
one single nucleotide substitution per site. The bootstrap values that had a probability of À50z were shown in the
tree.
Fig. 2. Phylogenetic tree of the nucleotide HA sequences of the Nagasaki isolates classified as cluster I against those
from A/Philippines/2001/2009, Mexican, and American isolates by the maximum-likelihood method. The bar in-
dicates one single nucleotide substitution per site. The bootstrap values that had a probability of À50z were
shown in the tree.
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A/Nagasaki/HA-33/2009 － 2.0 1
A/Nagasaki/HA-58/2009 ＋ 46 26
1): The average IC50 values of duplicate measurements are shown.
The fold increase in IC50 value compared to that of
A/Nagasaki/HA-6/2009.
identical HA nucleotide sequences. Between the end of
August 2009 and January 2010, 5 new clusters (II–VI)
emerged, and 3 of these (clusters III, IV, and VI) con-
tinuously advanced until February or March 2010.
Clusters II, III, and VI originated from A/Ankara/
08/2009 (Turkey), A/Ankara/10/2009 (Turkey), and
A/Mie/52/2009 (Japan), respectively. For strains in
clusters IV and V, no original viruses were identified in
the same cluster, but the viruses were more closely relat-
ed to several other foreign (A/Ankara/10/2009) and
Japanese (A/Mie/52/2009) isolates than other Nagasaki
isolates in the different clusters. These results suggest
that the onset of the pandemic influenza in Nagasaki
originated from a patient who returned from the Philip-
pines. Therefore, after September 2009, the spread of
different strains of pandemic influenza viruses replaced
the initially spreading virus.
To determine the evolutionary relationship to the
original pandemic virus, we also performed phylogenet-
ic analysis of the nucleotide HA sequences of Nagasaki
isolates classified as cluster I against those from
A/Philippines/2001/2009, Mexican, and American iso-
lates. The nucleotide divergence increased from the ini-
tially transmitted viruses in the countries of the origin of
the pandemic (Mexico and United States) to the
Nagasaki isolates (Fig. 2). A/Nagasaki/HA-6/2009,
isolated from a patient who returned from the Philip-
pines (collected on July 13, 2009), was phylogenetically
more similar to A/Philippines/2001/2009 (collected on
May 20, 2009) than to the other Nagasaki isolates classi-
fied into Nagasaki cluster I.
Sensitivity of Nagasaki isolates to oseltamivir in an in
vitro assay: To evaluate the oseltamivir resistance of
A/Nagasaki/HA-58/2009, which possesses a H275Y
mutation, we performed an in vitro oseltamivir-
resistance assay. The 50z inhibitory concentration
(IC50) for A/Nagasaki/HA-58/2009 was 26-fold higher
(46 mM) than that of A/Nagasaki/HA-6/2009 (1.8 mM),
which does not have the H275Y mutation (Table 3).
Similar sensitivity was observed between A/Nagasaki/
HA-6/2009 and A/Nagasaki/HA-33/2009. These data
clearly showed that A/Nagasaki/HA-58/2009 is sig-
nificantly less sensitive to oseltamivir, most likely due to
the H275Y mutation.
DISCUSSION
We herein report the characterization of the HA
genes of the pandemic (H1N1) 2009 influenza viruses
isolated in Nagasaki and their phylogenetic relation-
ships with global isolates. The HA genes of 75 viruses
collected in Nagasaki between July 2009 and March
2010 were analyzed. HA cleavage by a host protease is
an important step in the replication cycle of the influen-
za virus and results in increased infectivity by activating
the fusion potential (20,21). The HA of highly patho-
genic avian strains contains a conserved arginine or a
stretch of basic amino acids at the cleavage site (22).
However, the predicted amino acid sequences of the HA
of analyzed Nagasaki isolates did not contain such se-
quences. A similar observation in other pandemic
(H1N1) 2009 strains was reported by Itoh et al. (23).
The amino acid differences between the HA of
Nagasaki isolates and global isolates are summarized in
Table 2. By employing 3D structures to map amino acid
residues in the antigenic sites of HA, Igarashi et al.
showed that the HA1 antigenic structure of the pandem-
ic (H1N1) 2009 virus (A/California/04/2009) is similar
to that of the 1918 (H1N1) pandemic virus (24). Similar-
ly, Itoh et al. showed that appreciable neutralizing an-
tibodies against the A/California/04/2009 strain were
present in the sera collected from individuals born be-
fore 1918 (23). We further compared the amino acid
residues constituting the 4 antigenic sites of A/Califor-
nia/04/2009 with those of the Nagasaki isolates. Almost
all residues were highly conserved in the Nagasaki iso-
lates (data not shown), indicating that HA proteins
from the isolated viruses have an antigenic structure
similar to that of the 1918 (H1N1) pandemic virus. It is
worth noting that several amino acid differences in the
antigenic sites of Ca1 (T220S in A/Nagasaki/HA-6, 12,
14, 16, 17, 22, 28, 29, 59, 60, 63/2009, and A/
Nagasaki/HA-10-6/2010), Ca2 (A156D in A/Nagasaki/
HA-10-4, 5, and 10/2010 and D239E in A/
Nagasaki/HA-44 and 52/2009), and Sb (A203T in A/
Nagasaki/HA-10-13/2010 and D204G in A/Nagasaki/
HA-10-5, 6, and 9/2010) were also observed. Our data
suggest that an antigenic drift may have occurred during
the spread within the human population, which poten-
tially lowered the efficacy of pandemic influenza vac-
cines. To observe the pattern of spreading of the amino
acid mutations within HA antigenic sites, we plotted
these mutations in the phylogenetic tree (Fig. 1). In-
terestingly, T220S (located within Ca1) in cluster I seems
to have disappeared starting in August (except for
A/Nagasaki/HA-60/2009), and this mutation sporadi-
cally reemerged in clusters III and IV. On the other
hand, A156D (located within Ca2) in cluster V is likely
to have selectively emerged as a cluster V virus. These
findings will be useful as a reference for future studies
for estimating the mechanism of antigenic drift events.
The results of the phylogenetic analysis revealed that
the Nagasaki isolates could be classified into 6 main
clusters (I–VI) (Fig. 1). Almost all Nagasaki isolates col-
lected in the early season were classified into cluster I,
which most probably evolved from A/Nagasaki/HA-
6/2009 isolated from a patient who returned from the
Philippines. To confirm this, we further compared the
nucleotide sequences of HA of A/Nagasaki/HA-6/2009
with those from strains identified in the Philippines.
The nucleotide sequences of HA from the A/
Nagasaki/HA-6/2009 strain showed a significantly high
similarity with that of the A/Philippines/2001/2009 iso-
late (collected on May 20, 2009) (Fig. 2). These results
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raise the possibility that patient HA-6 had been infected
by the virus that had originated in the Philippines. The
Philippine isolate also showed higher similarities with
those identified in Mexico and the United States than
the Nagasaki isolates, and this isolate most likely origi-
nated from the countries in which the pandemic started.
The reason why the A/Nagasaki/HA-4/2009 and
A/Nagasaki/HA-9/2009 strains, apparently ``import-
ed'' from foreign countries, did not spread might be be-
cause of the rapid isolation and subsequent treatment of
the affected patients.
Sixteen strains with identical HA sequences (A/
Nagasaki/HA-11, 13, 24, 27, 30–40, and 42/2009) were
classified into cluster I. Among these strains, A/
Nagasaki/HA-13/2009 was isolated from a patient who
had symptoms after participating in the summer festival
held in Nagasaki (Table 1). Furthermore, 3 strains
(A/Nagasaki/HA-12, 14, 15/2009), isolated from par-
ticipants in the same festival, also appeared in cluster I.
Approximately 2,000 people from Nagasaki as well as
from outside the city participated in the festival. This
suggested that the initial spread of the pandemic (H1N1)
2009 influenza viruses occurred among those who par-
ticipated in the event.
From the end of August, 5 new phylogenetic clusters
appeared, and 3 of these (III, IV, and VI) continuously
spread until February (IV and VI) or March 2010 (III).
Clusters II, III, and VI originated from A/Ankara/
08/2009 (Turkey), A/Ankara/10/2009 (Turkey), and
A/Mie/52/2009 (Japan), respectively, as the estimated
original viruses. Strains in clusters IV and V without a
suspected origin were evolutionarily more closely relat-
ed to several other foreign (A/Ankara/10/2009) and
Japanese (A/Mie/52/2009) isolates than to other
Nagasaki isolates in the different clusters (Fig. 1). These
results imply that the mid- to late-season of the
Nagasaki pandemic may have resulted from different
isolates that originated outside of Nagasaki. Through
this study, we succeeded in simulating how pandemic in-
fluenza viruses spread in a region far from the pandemic
origin. In several countries, quarantine strategies tended
to be thought of as relatively ineffective. However, on
the basis of the data from this study, such strategy is
likely to be effective in the case of a small city such as
Nagasaki. Our findings emphasize the importance of
quick tests at airports or seaports and the use of quaran-
tine in preventing the spreading of influenza viruses.
In the present study, we also analyzed the NA se-
quence of the isolated viruses. We detected one H275Y
mutant isolated from patient HA-58 who had aggravat-
ed symptoms despite treatment with oseltamivir in
October 2009 (Table 1). The mutant strain was less
sensitive to oseltamivir compared with other Nagasaki
isolates without the H275Y mutation in the NA se-
quence as shown in an in vitro oseltamivir-resistance as-
say (Table 3). In the past, the H275Y mutant had been
recognized as being of relatively low clinical conse-
quence due to reduction of the NA activity required for
viral replication (25). However, the spread of osel-
tamivir-resistant influenza viruses was very rapid, be-
cause more than 90z of the seasonal H1N1 influenza
viruses isolated during the 2008/2009 season were osel-
tamivir resistant (14). In our present study, the other 74
Nagasaki isolates were not found to be H275Y mutants.
Therefore, it is important to pay close attention to the
emergence of oseltamivir-resistant viruses.
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